AI in Healthcare Innovation

Navigating AI Use Cases in Healthcare: From Hype to Evidence! I’ve mapped the rapidly expanding universe of AI use cases in healthcare from early-stage “on the horizon” innovations to “safe bets” that are already backed by strong evidence. I analyzed them on two scales, little evidence to evidence-based; and low risk to high risk. This yielded four groups: 1) Speculative and risky (little evidence, high risk) 2) On the horizon (little evidence, low risk) 3) Handle with care (evidence-based, high risk) 4) Safe bet (evidence-based, low risk) I hope this infographic helps clarify the path ahead: which solutions demand more research and caution (autonomous AI prescribing, mental health chatbots), and which are ready for prime time (AI-powered clinical documentation, radiology analysis, ECG interpretation). I'm curious to hear what you see significantly differently! #DigitalHealth #HealthTech #AI #Future #HealthcareInnovation

Today in Cell, we published new research showing how AI can help accelerate cancer discovery. With GigaTIME, we can now simulate spatial proteomics from routine pathology slides, enabling population-scale analysis of tumor microenvironments across dozens of cancer types and hundreds of subtypes.   Developed in partnership with Providence and the University of Washington, our hope is that this work helps scientists move faster from data to insight, revealing new links between genetic mutations, immune activity, and clinical outcomes, and ultimately improving health for people everywhere. https://lnkd.in/dSpPdtzz

The Agentic Enterprise is driving profound change across every industry, but nowhere are the stakes higher than in healthcare. There is an incredible opportunity to elevate the work of healthcare professionals and deliver stronger care for patients around the world. In an essay for TIME, Murali Doraiswamy, professor of medicine at Duke University, and I discuss how AI is revolutionizing medicine, including: • Flagging subtle abnormalities in scans and slides that a human eye might miss. • Speeding up the discovery of drugs and drug targets. • Providing patients faster and more personalized support, from scheduling to flagging side effects But we’ve also seen that over-reliance on AI can lead to “deskilling” — in which medical professionals become less effective. That underscores the importance of approaches that keep humans at the center, such as the Intelligent Choice Architecture (ICA), where AI systems don’t make decisions but nudge providers to take a second look at results, weigh alternatives, and stay actively engaged in the process. The future of work is humans and AI agents working together. If we commit to designing systems that sharpen our abilities, we can combine the promise of AI with the critical thinking, compassion, and real-world judgment that only humans bring. https://lnkd.in/gqkTUfb6

We just ran the largest AI trial in NHS history. 205 primary care practices. 1.5 million patients. A stethoscope that detects heart failure, atrial fibrillation, and valvular heart disease in 15 seconds — with regulatory approval and strong clinical evidence behind it. The technology worked. The population-level outcomes didn't move. That gap is the most important story in health AI right now — and it has nothing to do with algorithms. The TRICORDER trial, just published in The Lancet, found that when clinicians actually used the AI stethoscope, they detected 2.33× more heart failure, 3.45× more atrial fibrillation, and nearly twice as much valvular heart disease. But 40% of practices had stopped using the device entirely within 12 months. Why? No EHR integration. Extra workflow steps. A 15-second recording that added minutes of friction to an already stretched consultation. Clinicians weren't hostile. They were exhausted. And when asked what would most improve uptake, they ranked workflow integration above financial incentives. They didn't want to be paid more to use it. They wanted it to stop getting in their way. This is the lesson the health AI field keeps learning — and keeps forgetting: → Regulatory approval is not adoption. → Algorithmic accuracy is not clinical impact. → Integration is not a feature. It is the product. The technology works. The potential is real. The gap between potential and reality is almost entirely an implementation problem. And implementation problems are solvable — if we fund them, study them, and take them as seriously as we take the algorithms. I've written about what TRICORDER really teaches us — and what needs to change if AI is going to deliver on its promise in health care. Read the full blog here: https://lnkd.in/eNSAsZw8 #HealthAI #DigitalHealth #Innovation #HealthcareLeadership #ImplementationScience #AIinMedicine

🚨 AI JUST HIT ROCHE’S EARNINGS CALL 🚨 Roche’s Q3 2025 earnings call quietly revealed something bigger than a quarterly update — it showed where diagnostics is heading. They announced the Kidney Klinrisk Algorithm — an AI-driven risk stratification tool that just received its CE mark in Europe. This isn’t just a new test. It’s the start of a new category of diagnostics — where routine lab results, imaging, and patient data combine to predict risk before symptoms even appear. “By combining AI with routine tests, Roche helps physicians identify patients at risk of kidney function decline early on, enabling more informed and confident decision-making.” 💡 The signal beneath the noise: ✅ AI + Multi-Modal Data — Fusing clinical, biomarker, imaging, and real-world evidence to find patterns humans can’t see. ✅ Biomarker-Driven Precision — Identifying patient subgroups that respond differently, turning reactive testing into proactive insight. ✅ Data Governance & Traceability — Building regulated, audit-ready data environments to support CE-marked and FDA-cleared algorithms. ✅ Speed to Insight — Automating model development pipelines so clinicians don’t wait months for answers that data could reveal in days. For an industry where Diagnostics has been the slowest to digitize, this marks a real inflection point: from test results ➜ to algorithms ➜ to earlier, smarter interventions. Roche may have lit the spark — but the opportunity runs across the entire ecosystem. The companies who can unify multi-omics, imaging, and clinical data under a compliant, AI-ready framework will define the next era of precision medicine.

This paper explores how AI is shifting from a promising concept to practical application in clinical medicine, highlighting its transformative potential, existing limitations, and future needs. 1️⃣ AI now rivals expert clinicians in diagnostic tasks—deep convolutional neural networks match dermatologists in classifying skin lesions, and ML improves cancer prognosis prediction accuracy. 2️⃣ LLMs like ChatGPT support emergency care decisions, generate clinical notes, and aid surgical workflows with up to 90% instrument recognition accuracy. 3️⃣ AI enhances operational efficiency by automating documentation, enabling real-time translation, and optimizing EHR management through autoML. 4️⃣ Core limitations include lack of transparency ("black box" AI), bias in training data, poor generalizability, usability gaps in clinical settings, and weak regulatory oversight. 5️⃣ Ethical concerns focus on accountability, clinician overreliance, patient privacy, and informed consent in data use, especially affecting marginalized groups. 6️⃣ Explainable AI (XAI) is essential to gain clinician trust—tools must align with clinical reasoning, not just technical transparency. 7️⃣ Bias mitigation requires more than diverse datasets; adaptive learning and real-time fairness audits are needed for equitable outcomes. 8️⃣ Real-world adoption challenges persist—future studies must evaluate AI’s impact on workload, decision-making, and patient outcomes in dynamic settings. 9️⃣ Regulatory evolution is critical—unlike drugs, AI tools often bypass RCTs. Continuous post-deployment monitoring is needed to ensure safety and accountability. 🔟 The paper calls for interdisciplinary collaboration and deliberate implementation strategies to ensure AI enhances care rather than widens healthcare inequities. ✍🏻 Ariana Genovese, Sahar Borna, Cesar Abraham Gomez Cabello, MD, Syed Ali Haider, Prabha Srinivasagam, Maissa Trabilsy, Antonio Jorge de Vasconcelos Forte. From Promise to Practice: Harnessing AI’s Power to Transform Medicine. Journal of Clinical Medicine. 2025. DOI: 10.3390/jcm14041225 ✅ Sign up for our newsletter to stay updated on the most fascinating studies related to digital health and innovation: https://lnkd.in/eR7qichj

Astellas Pharma becomes latest pharma giant to join Evinova's AI platform, following Bristol Myers Squibb and parent AstraZeneca in backing cross-industry clinical trial collaboration >> 🔘 Three major pharma companies are now sharing operational clinical trial data with Evinova's AI platform, marking a rare moment of cross-industry collaboration in drug development 🔘 The platform uses multi-agent AI to tackle one of pharma's most persistent problems: fragmented systems and manual processes that drag out timelines and inflate costs. 🔘 It converts protocols into machine-readable formats and generates optimized study designs in minutes, benchmarked across cost, timelines, patient experience, and even carbon footprint, replacing weeks of manual work. 🔘 A single clinical trial requires over 200 interconnected document types. AI authoring agents now handle intelligent recommendations across regulatory, scientific, and operational inputs, cutting costly protocol amendments 🔘 Early results show 5 to 7 percent savings minimum per study, translating to hundreds of millions of dollars across a top-10 pharma portfolio 🔘 The architecture is modular and cloud-native, letting organizations plug in their own AI models with built-in privacy and regulatory compliance across global markets 💬 The broader signal here: clinical development is finally moving from a document-heavy, siloed process to an AI-first workflow, and the opt-in data sharing model could set a new industry standard for how sponsors learn from each other #digitalhealth #pharma #AI

AI in healthcare is not simply another technology upgrade. It is a matter of trust, safety, and ultimately, human life. In many sectors, an AI error might lead to inconvenience or financial loss. In healthcare, an AI error can mean a missed diagnosis, an inappropriate treatment pathway, or avoidable harm. That is why AI adoption in healthcare must be held to a higher standard than in almost any other industry. It requires deeper validation, stricter governance, and human guardrails at every stage. A framework I find particularly helpful is 𝐀𝐈 + 𝐑𝐀𝐂𝐓⁣, strengthened through a Human-Centred AI lens. 𝐑 = 𝐑𝐞𝐚𝐝𝐢𝐧𝐞𝐬𝐬⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣The risk begins long before deployment. If clinical data is incomplete, biased, or unrepresentative, AI systems can fail quietly, often affecting the most vulnerable populations first. Readiness must include: →Data integrity and provenance →Regulatory compliance →Clear clinical problem definition →Ethical and patient safety accountability 𝐀 = 𝐀𝐝𝐨𝐩𝐭𝐢𝐨𝐧⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣In healthcare, adoption is not about installing a tool, it is about integrating it into clinical judgment. The risk is over-reliance, alert fatigue, or the introduction of friction into already pressured workflows. Human-centred adoption means: →Clinicians remain firmly in the loop →AI outputs are explainable and challengeable →Training supports human-AI collaboration, not replacement 𝐂 = 𝐂𝐚𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐲⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣Healthcare AI is not static. Models drift, populations change, and clinical practice evolves. The risk is that a system that appears safe today may not remain safe tomorrow. Capability requires: →Continuous monitoring and evaluation →Governance structures spanning clinicians, data, ethics and risk →Ongoing validation, not one-off approval 𝐓 = 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣True transformation is not automation for its own sake. The risk of scaling without safeguards is amplified inequity, diminished patient trust, and decision-making that feels outsourced. Transformation must prioritise: →Better patient outcomes and experience →Equity across communities →Shared decision-making, supported, not replaced, by AI The central truth is this: 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐀𝐈 𝐢𝐬 𝐧𝐨𝐭 𝐜𝐨𝐧𝐬𝐮𝐦𝐞𝐫 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲. 𝐈𝐭 𝐢𝐬 𝐬𝐚𝐟𝐞𝐭𝐲-𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥.⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣ ⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣⁣Progress must be ambitious, but responsibility must be uncompromising. The question is not whether AI will shape the future of care. It is whether we shape it with the rigour, humility, and human focus that patients deserve. What is the single most important gate check you insist on before scaling AI in clinical environments? ♻️ Share if this resonates ➕ Follow (Jyothish Nair) for reflections on AI, change, and human-centred AI #ResponsibleAI #AI #DigitalTransformation #HumanCentredAI

The NYT just reported that patients are uploading entire medical records into chatbots - but the risks are not what most people think. Patients are pasting labs, imaging, clinical notes, and oncology reports directly into LLMs. • 26-year-old told her labs “most likely” indicated a pituitary tumor. MRI: normal • 63-year-old advised to escalate to catheterization. Found ~85% LAD stenosis Because of how the chatbot responds, many assume the AI reasons about their symptoms and medical record the same way a clinician does. But AI systems are capable of both meaningful help and serious error, without any calibration signal visible to the user. Most worry about wrong AI recommendations. But the bigger risk is what the AI does not say. 📊 Harm preprint study A new Stanford-Harvard study (David Wu, MD, PhD, Fateme (Fatima) Nateghi, Adam Rodman, Jonathan H. Chen et al.) evaluated 31 models on 100 real outpatient eConsult cases across 10 specialties: - 4,249 management actions - 12,747 expert ratings Severe harm per 100 cases: - Best models: ~12–15 - Worst models: ~40 ~77% of severe harms were omissions: - Not ordering a critical test - Missing a needed referral - Neglecting follow-up suggestions 🔷 Additional findings: 1) Top models outperformed generalists using conventional resources (though these were difficult eConsult cases that PCPs were posing to specialists) 2) No link between safety and model size, recency, “reasoning modes,” or standard benchmarks 3) Multi-agent + RAG approaches reduced harm; heterogeneous ensembles had ~6× higher odds of top-quartile safety 📌 Implications When a patient asks AI for medical advice, the primary risk is not incorrect recommendations. It's neglecting critical actions a clinician might suggest (notably, humans also make a lot of mistakes). ⚠️ Why this matters 1) 2/3 of US physicians report using LLMs, and millions of patients. Errors will become more subtle as models get better. Both harms of omissions and commission will become harder for clinicians (and especially patients) to detect. 2) Sampling a few outputs is not enough: clinical AI evaluation needs explicit, systematic harm measurement on real cases, not just performance or accuracy on knowledge benchmarks. 3) If we don’t measure omission harms, we will systematically underestimate risk. 🔴 Open Call: State of Clinical AI Report (Jan 2026) The ARISE Network (Stanford + Harvard) is compiling a State of Clinical AI Report for 2026. Audience: health system leaders, clinicians, researchers, tech/pharma, media, investors 2025 peer reviewed and preprint studies within scope: • Clinical AI (doctor- or patient-facing) • Benchmarks, evaluations, real-world deployments, prospective trials • Workflow, outcomes, and implementation studies 📅 Submission deadline: Dec 21, 2025 - Comment with study link + 1–2 sentences on key findings and why it matters - We will follow up with a one-slide reference example for invited submissions

AI’s impact on medicine is no longer theoretical—it’s redefining daily clinical practice, medical research, and the very fabric of physician training. Breakthroughs like Google DeepMind’s AlphaFold2 have let researchers predict the structure of nearly every known protein, accelerating new drug development and igniting a wave of biotech innovation. AI models are now outperforming traditional methods—detecting cancer, forecasting disease progression, and driving efficiencies in active compound discovery. On the operational side, hospitals are leveraging large language models to automate clinical documentation and summarize complex records. The result: clinicians spend less time on paperwork—and more time with patients—helping combat burnout and improve satisfaction for both sides. Medical education is also evolving. Universities such as Stanford and Mount Sinai are weaving AI training into their curricula, recognizing that tomorrow’s doctors need to not only master clinical knowledge but also the critical thinking to collaborate with AI tools effectively. Simulated surgical training, AI-powered feedback, and new pharmacy protocols show that the skillset for modern medicine is expanding—and institutions are responding accordingly. Caution is warranted: Algorithmic bias, data privacy, and the need for robust validation remain real concerns. Yet the pace of deployment and the scope of benefit make clear that AI is not a distant disruptor; it’s a core enabler of the industry’s future. Now is the time for healthcare leaders, educators, and innovators to shape policies, invest in talent, and reimagine workflows. Let’s ensure that AI’s integration into medicine truly elevates care, training, and research for all. https://lnkd.in/gwi3htAJ #AIinMedicine #HealthcareInnovation #MedicalResearch #ClinicalAI #HealthTech #AIEducation #FutureOfMedicine #DigitalHealth #MedTech #HealthcareLeadership